TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03778814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCR-T cells
Description: Engineering TCR-T cells targeting lung tumor and other solid tumor will be transfused back the patients.
Study: NCT03054207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 300Mg Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 300Mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel 60Mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 60Mg
Study: NCT03096925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided self-help
Description: Web-based guided self-help intervention
Study: NCT03374085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: CC-92480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: CC-92480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study: NCT03265535

Intervention type: DIAGNOSTIC_TEST
Intervention: Single-Scan Two-Injection Protocol
Description: Single-Scan Two-Injection Protocol

Intervention type: DIAGNOSTIC_TEST
Intervention: Single-Scan Two-Injection Protocol
Description: Single-Scan Two-Injection Protocol
Study: NCT03388255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polydeoxyribonucleotides
Description: Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use i.m.~The study period consists of the following phases:~* Treatment period: 3 months (daily i.m. treatment with PLACENTEX ® Polydeoxyribonucleotide 5.625 mg/3 ml for parenteral use, one vial per day for intra-muscular administration).~* Follow up period: 3 months after end of active treatment, without study medication.
Study: NCT02751723

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires

Intervention type: OTHER
Intervention: validated questionnaires
Study: NCT01678235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Study: NCT01684761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tcelna
Description: Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
Study: NCT01524055

Intervention type: DEVICE
Group type: OTHER
Intervention: Single-Balloon-Enteroscopy with Air as insufflation gas.
Description: Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.

Intervention type: DEVICE
Group type: OTHER
Intervention: Single-Balloon-Enteroscopy with CO2 as insufflation gas.
Description: Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
Study: NCT03271658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web based life support patient decision aid
Description: The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision coaching
Description: During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
Study: NCT02792179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]RO6958948
Description: Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of \[18F\]RO6958948 injected will be less than or equal to (\</=) 10 micrograms (µg), injection volume \</=20 mL. Target injected activity for \[18F\]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie \[mCi\]).
Study: NCT03574441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm dressing + catheter support pad
Description: Tegaderm TM is a transparent tape. This intervention adds a support pad that comes in the epidural kit to help secure the catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm dressing + Steri-strip dressing
Description: Tegaderm TM is a transparent tape. This intervention adds Steri Strips TM of tape to help secure the catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm dressing only
Description: Tegaderm TM is a transparent tape. This intervention uses only Tegaderm to secure the catheter
Study: NCT04259294

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caspar Telerehabilitation
Description: The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caspar Telerehabilitation
Description: The experimental group will receive home-based treatment program through mobile apps while control group will receive through a written home program sheets. The training contents will be equivalent, including trunk and lower limb strengthening and stretching, coordination, balance, and functional exercises that will be related to patients' daily living activities in their home.~The frequency and duration of the home program will be compromised by both the therapist and the patient. The videos of the home program will be sent to patients' app in smartphone by the therapist in the experimental group. Patients will perform the exercises while watching the videos in the app. After each exercise will be done, patient's performance feedback will be captured by the smartphone and will be sent back to the case therapist each time through the app while those in the control group will record their performance in a log sheet given by the therapists.
Study: NCT00752687

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-072
Description: Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
Study: NCT00146757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 100 U/kg every week

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
Description: 200 U/kg every week (Week 26 onwards)
Study: NCT04585646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orion daily disposable contact lens
Description: Subjects will be randomized to wear Orion lens for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orion daily disposable contact lens
Description: Subjects will be randomized to wear Orion lens for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini daily disposable contact lens
Description: Subjects will be randomized to wear Gemini lens for 2 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gemini daily disposable contact lens
Description: Subjects will be randomized to wear Gemini lens for 2 weeks.
Study: NCT01248702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of the ICD Critical Pathway
Description: The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
Study: NCT03198598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga
Description: The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga app
Description: The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
Study: NCT05532436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Exercise
Description: It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
Study: NCT04227951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avoid drain placement
Description: In No Drain arm (experimental) no abdominal drain is placed at the end of the operation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Drain placement
Description: In Drain arm (sham comparator) an abdominal drain is inserted in the abdomen from the right flank, passing below the liver (close to the duodenal stump) with the apex behind the esophago-jejunal (in total gastrectomy) or gastro-jejunal (in subtotal gastrectomy) anastomosis.
Study: NCT04095078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIMEOX
Description: Use without obligation, in autonomous and at home of the bronchial clearance device: SIMEOX
Study: NCT04706754

Intervention type: OTHER
Intervention: Questionnaires
Description: Prospectively enrolled participants will be provided with survey packets comprised of different questionnaires at the initial/baseline visit and every 3 months and/or whenever there is an update in their treatment protocol
Study: NCT00463268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate
Description: alendronate 70 mg every 2 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Calcium 500 mg and vitamin D supplementation according to serum level

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium/Vitamin D
Description: Calcium 500 mg and vitamin D supplementation according to serum level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical placebo every 2 weeks
Study: NCT02448225

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FDG PET/CT - standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo 18F-FSPG PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorodeoxyglucose F-18
Description: Undergo 18F-FDG PET/CT - standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 L-glutamate Derivative BAY94-9392
Description: Undergo 18F-FSPG PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo 18F-FDG PET/CT - standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo 18F-FSPG PET/CT
Study: NCT02924298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLIMM
Description: Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLIMM
Description: Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
Study: NCT01430806

Intervention type: DRUG
Group type: OTHER
Intervention: Dronedarone arm
Description: PO Dronedarone 400 mg BID

Intervention type: DRUG
Group type: OTHER
Intervention: Dronedarone
Description: Dronedarone PO 400 MG BID
Study: NCT02047825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limbs intervention
Description: An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual treatment
Description: Occupational therapy and physiotherapy, twice a week, as usual.
Study: NCT04749342

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Treatment
Description: Physical Therapy sessions for treatment of advanced Lymphedema Cases

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy Treatment
Description: Physical Therapy sessions for treatment of advanced Lymphedema Cases
Study: NCT03214133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epicatechin-rich cocoa dose response
Description: Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Epicatechin-rich cocoa vs placebo on performance
Description: An optimized dose of epicatechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
Study: NCT00000125

Intervention type: DRUG
Group type: OTHER
Intervention: Topical ocular hypotensive eye drops.
Description: Topical ocular hypotensive eye drops.
Study: NCT02859961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 (350 mg)
Description: PRO 140 350 mg (175 mg/mL) SC injection per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 (525 mg)
Description: PRO 140 525 mg (175 mg/mL) SC injection per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 (700 mg)
Description: PRO 140 700 mg (175 mg/mL) SC injection per week
Study: NCT00889226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitavastatin
Description: Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C \<100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
Study: NCT03889431

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine capsule
Description: 225 µg of iodine daily as a capsule of potassium iodide

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iodized Salt
Description: 450 g iodized salt provided for the household weekly. Salt iodine content was 30 to 40 mg iodine /kg salt as KIO3
Study: NCT03089554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Intervention
Description: Therapeutic Intervention
Study: NCT02429622

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage once respectively

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage once respectively

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage once respectively

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT simultaneous integrated boost
Description: To achieve a prophylactic dosage and radical dosage once respectively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Radical esophagectomy 4-6 weeks after neoadjuvant therapy
Study: NCT04247009

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal based on red meat, fish products or vegan products
Description: Three meals will be served

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal based on red meat, fish products or vegan products
Description: Three meals will be served

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal based on red meat, fish products or vegan products
Description: Three meals will be served

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal based on red meat
Description: Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meal based on red meat
Description: Matched Controls will be served only one meal of meat to compare response between (non-RA) matched controls and patients with RA
Study: NCT02178553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal Bupivicaine (Exparel)
Study: NCT04141254

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing and educative components
Description: The patient will receive early debriefing and enhanced educative components added to a standardized visit at one month

Intervention type: OTHER
Group type: OTHER
Intervention: Without debriefing and educative components
Description: Patient will receive a standardized visit alone (without debriefing and enhanced educative components ) at one month
Study: NCT03559920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sedate using sevoflurane via anesthetic conserving device(ACD, Anaconda®) after surgery
Description: The investigators sedate the patients in the ICU for several days after head \& neck surgery using sevoflurane via anesthetic conserving device in sevoflurane group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sedate using propofol.
Description: Retrospectively, the investigators compare the sevoflurane group with intravenous sedation group using propofol.
Study: NCT00151554

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICU-specific information program
Description: The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
Study: NCT00764751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 19123 Cream (calcipotriol plus LEO 80122)
Description: Once daily application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovonex® cream
Description: Twice daily application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cream vehicle
Description: Twice daily application
Study: NCT00168480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: 100 U, repeated treatments at \> 4 month intervals up to Month 32, over a 36-month study period